In this three part series, Zayed Al Jamil and Holly Tunnah discuss the key points addressed in the New Technologies Formation report and in particular, the potential implications for businesses.
Topic: Blog-postSubscribe to Blog-post
Who controls the works produced by artificial intelligence?
Seiko Hidaka and Will Garton discuss the role of Intellectual Property in a world where the machine is creating new and better things autonomously.
A Legal Framework for Artificial Intelligence
IP Partner Maya Medeiros discusses the applications and legal definitions of artificial intelligence, and where law applies to particular AI processes or systems.
Artificial Intelligence and Separate Legal Personality
As artificial intelligence becomes more ubiquitous, the scope for economic loss or physical damage – on a B2B or B2C basis - inevitably grows too. James Russell and Paimon Abedi discuss the impact of AI.
BoE and FCA joint report on machine learning in UK Financial Services
Imogen Garner and Albert Weatherill discuss the joint report published by Bank of England and the FCA on machine learning in UK financial services.
AI as a solution for cybersecurity problems in M&A deals
This blog post explores the immense potential of Artificial Intelligence as a solution for cybersecurity vulnerabilities in M&A deals.
CIIs – The Australian Full Court Encompass Decision
IP lawyers Harrison Ottaway and Helen Macpherson discuss the contentious topic of the patentability of computer implemented inventions (CII) in Australian patent law.
Deepfakes: Fake videos need real remedy
Deepfakes appear genuine, with creators using AI and photos of nonconsenting people to make footage. IP partner Daniel Daniele discusses its malicious uses and legal advice for victims.
Vestager’s Digital Antitrust Blueprint
Effects of Commissioner Vestager’s unprecedented nomination to a second term as Competition Commissioner and dual mandate as Executive Vice-President for a Europe fit for the Digital Age (Digital Commissioner).
AI and Drug Discovery, Part 3: Protecting the Value of Data in Collaborations
In Part 3, we highlight some of the legal issues surrounding the use of AI/ML in collaborative drug discovery and some solutions for addressing these issues.